CVA 21

Drug Profile

CVA 21

Alternative Names: Cavatak; Coxsackievirus A21; CVA-21

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator ViroTarg
  • Developer Viralytics
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action CD55 antigen inhibitors; Cell death stimulants; Intercellular adhesion molecule 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Bladder cancer; Solid tumours
  • Suspended Head and neck cancer
  • No development reported Breast cancer; Chronic lymphocytic leukaemia; Glioma; Lung cancer; Mesothelioma; Multiple myeloma; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 11 Aug 2016 Viralytics completes the phase I CANON trial in Bladder cancer (Monotherapy, Combination therapy) in United Kingdom (NCT02316171)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Malignant-melanoma(Late-stage disease) in Australia (Intratumoural, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Australia (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top